Want to see HK:2216 full AI Analyst Report?
Broncus Holding Corp. (2216) AI Stock Analysis
Top Page
Broncus Holding Corp.
(HKEX:2216)
The score is held down primarily by very weak financial performance—sharp revenue deterioration, continued large losses, and ongoing cash burn—only partly offset by a low-leverage balance sheet. Technicals are moderately supportive in the short term (price above key short/mid DMAs and positive MACD) but are tempered by overbought signals and a still-weak long-term trend. Valuation is also challenged due to loss-making results (negative P/E) and no provided dividend yield.
Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 305.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 535.04K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 1.81
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 195
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Broncus Holding Corp. Business Overview & Revenue Model
Company Description
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international...
How the Company Makes Money
null
Broncus Holding Corp. Financial Statement Overview
Summary
Overall financial quality is weak. The income statement is severely pressured by an ~97% revenue collapse and persistent deep losses (including negative gross profit in the latest year), and cash flows remain negative with ongoing free cash flow burn despite slight improvement. The balance sheet is a relative support with minimal leverage and sizable positive equity, but negative ROE persists due to continued losses.
Income Statement
14Very NegativeBalance Sheet
62PositiveCash Flow
23Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.80M | 174.00K | 8.13M | 10.26M | 9.41M | 10.89M |
| Gross Profit | -2.43M | -917.00K | 6.14M | 7.23M | 7.32M | 8.74M |
| EBITDA | -20.28M | -22.32M | -17.88M | -25.06M | -29.86M | -233.31M |
| Net Income | -18.22M | -17.88M | -15.30M | -28.09M | -28.04M | -236.18M |
Balance Sheet | ||||||
| Total Assets | 150.57M | 156.11M | 175.90M | 195.81M | 221.94M | 252.81M |
| Cash, Cash Equivalents and Short-Term Investments | 99.28M | 69.24M | 139.11M | 156.88M | 187.91M | 227.21M |
| Total Debt | 244.97K | 16.00K | 318.00K | 2.35M | 1.47M | 1.95M |
| Total Liabilities | 7.70M | 6.17M | 6.42M | 10.44M | 8.48M | 10.39M |
| Stockholders Equity | 142.85M | 149.94M | 169.48M | 185.37M | 213.46M | 242.42M |
Cash Flow | ||||||
| Free Cash Flow | -9.36M | -10.04M | -10.32M | -26.84M | -31.81M | -33.38M |
| Operating Cash Flow | -9.14M | -10.00M | -10.00M | -26.13M | -30.95M | -31.49M |
| Investing Cash Flow | 5.55M | -877.29K | -25.91M | 5.49M | -87.57M | -1.75M |
| Financing Cash Flow | -2.82M | -4.60M | -1.02M | -1.46M | -572.00K | 241.82M |
Broncus Holding Corp. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 0.58 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.65, and below the 200-day MA of 1.06, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.33 is Neutral, neither overbought nor oversold. The STOCH value of 35.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.
Broncus Holding Corp. Peers Comparison
Overall Rating
HK:161267Neutral
HK:223559Neutral
HK:229746Neutral- HK:221646Neutral
HK:225242Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 67Neutral | HKD 468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% |
| HK:2235 | 59Neutral | HKD 2.82B | 27.65 | 4.08% | ― | 94.80% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2297 | 46Neutral | HKD 241.03M | -2.97 | -19.46% | ― | 4.35% | 43.23% |
| HK:2216 | 46Neutral | HKD 306.67M | -1.98 | -12.45% | ― | ― | ― |
| HK:2252 | 42Neutral | HKD 21.97B | -74.88 | -52.78% | ― | 114.97% | 63.21% |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2216 | Broncus Holding Corp. | 0.58 | -2.00 | -77.52% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.92 | -49.33% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.71 | -0.10 | -12.24% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.70 | -0.20 | -2.90% | |
| HK:2252 | Shanghai MicroPort MedBot (Group) Co., Ltd. Class H | 21.18 | -5.94 | -21.90% | |
| HK:2297 | Rainmed Medical Limited | 0.17 | -0.12 | -40.69% |
Broncus Holding Corp. Corporate Events
Broncus Grants Performance-Based RSU Awards to Employees
Broncus Holding Corporation has granted 2,695,482 restricted share unit awards, equivalent to about 0.51% of its issued share capital, to six employees under its RSU scheme. The awards, granted at no purchase price and funded by shares already held b...
Broncus ends major share transfer deal, to recover US$5.5 million deposit
Broncus Holding Corporation has terminated a planned share transfer deal after its wholly owned unit, Broncus China Holding Corporation, and seller Max Grand Limited mutually agreed to end the transaction. Under the termination arrangement signed on...
Broncus Holding Delays Circular on Major Share Acquisition to September
Broncus Holding Corporation has announced a further delay in sending a shareholder circular related to a major transaction involving the additional acquisition of shares in a target company, first disclosed in March 2026. The company now expects to d...
Broncus Holding to Publish Unaudited Interim Results for First Half of 2026
Broncus Holding Corporation has released its unaudited interim results for the six months ended June 30, 2026, fulfilling disclosure requirements of the Hong Kong listing rules. The full interim report, including financial highlights, business update...
Broncus Holding Sets Board Meeting to Approve 2026 Interim Results
Broncus Holding Corporation has scheduled a board meeting for August 27, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026. The planned publication of these interim results will provide investors and oth...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026